PMID- 23983807
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20130828
LR  - 20211021
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2013
DP  - 2013
TI  - Electroacupuncture and rosiglitazone combined therapy as a means of treating 
      insulin resistance and type 2 diabetes mellitus: a randomized controlled trial.
PG  - 969824
LID - 10.1155/2013/969824 [doi]
LID - 969824
AB  - Aims. To evaluate the efficacy of rosiglitazone (TZD) and electroacupuncture (EA) 
      combined therapy as a treatment for type 2 diabetes mellitus (T2DM) patients by 
      randomized single-blind placebo controlled clinical trial. Methods. A total of 31 
      newly diagnostic T2DM patients, who fulfilled the study's eligibility criteria, 
      were recruited. The individuals were randomly assigned into two groups, the 
      control group (TZD, N = 15) and the experimental group (TZD + EA, N = 16). 
      Changes in their plasma free fatty acid (FFA), glucose, and insulin levels, 
      together with their homeostasis model assessment (HOMA) indices, were 
      statistically compared before and after treatment. Hypoglycemic activity (%) was 
      also compared between these two groups. Results. There was no significant 
      difference in hypoglycemic activity between the TZD and TZD + EA group. The 
      effectiveness of the combined therapy seems to derive from an improvement in 
      insulin resistance and a significant lowering of the secreted insulin rather than 
      the effect of TZD alone on T2DM. The combined treatment had no significant 
      adverse effects. A lower plasma FFA concentration is likely to be the mechanism 
      that causes this effect. Conclusion. This combined therapy seems to suppress 
      endogenous insulin secretion by improving insulin resistance via a mechanism 
      involving a reduction in plasma FFA. This trial is registered with 
      ClinicalTrials.gov NCT01577095.
FAU - Lin, Rong-Tsung
AU  - Lin RT
AD  - Department of Internal Medicine and Emergency Medicine, Division of Endocrinology 
      and Metabolism, Tungs' Taichung Metro Harbor Hospital, Taichung County, Taiwan.
FAU - Pai, Huei-Chin
AU  - Pai HC
FAU - Lee, Yu-Chen
AU  - Lee YC
FAU - Tzeng, Chung-Yuh
AU  - Tzeng CY
FAU - Chang, Chin-Hsien
AU  - Chang CH
FAU - Hung, Pei-Hsiu
AU  - Hung PH
FAU - Chen, Ying-I
AU  - Chen YI
FAU - Hsu, Tai-Hao
AU  - Hsu TH
FAU - Tsai, Chin-Chun
AU  - Tsai CC
FAU - Lin, Jaung-Geng
AU  - Lin JG
FAU - Chang, Shih-Liang
AU  - Chang SL
LA  - eng
SI  - ClinicalTrials.gov/NCT01577095
PT  - Journal Article
DEP - 20130729
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC3745852
EDAT- 2013/08/29 06:00
MHDA- 2013/08/29 06:01
PMCR- 2013/07/29
CRDT- 2013/08/29 06:00
PHST- 2013/02/21 00:00 [received]
PHST- 2013/04/19 00:00 [revised]
PHST- 2013/04/28 00:00 [accepted]
PHST- 2013/08/29 06:00 [entrez]
PHST- 2013/08/29 06:00 [pubmed]
PHST- 2013/08/29 06:01 [medline]
PHST- 2013/07/29 00:00 [pmc-release]
AID - 10.1155/2013/969824 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2013;2013:969824. doi: 10.1155/2013/969824. 
      Epub 2013 Jul 29.